Zp17
Zp17 is a PROTAC degrader that targets the STING protein for degradation by recruiting cereblon, with a DC50 of 956 nM in THP-1 cells. Zp17 induces proteasome-dependent STING protein degradation and inhibits the activity of the STING signaling pathway. Zp17 alleviates renal function injury in a mouse model of acute kidney injury induced by Cisplatin (HY-17394). Zp17 exhibits STING-degrading activity in human monocytes and STING-inhibiting activity in mouse macrophage reporter cells. Zp17 can be used for research on inflammation and acute kidney injury.
(Pink: STING Target protein ligand; Blue: Cereblon ligand (HY-41547); Black: linker (HY-133388)).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C34H42N6O5
- 分子量:614.73
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
PROTACs アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
体外実験
Zp17 (0.3-20 μM; 1.5-24 h) potently inhibits STING pathway activation in RAW-Lucia cells, with an IC50 of 1.06 μM, and exhibits stronger activity than H151 and SP23[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:THP-1
-
Concentration:Zp17 5 μM; MG132 (HY-13259) 0.06-1 μM or 1 μM; Chloroquine (HY-17589A) 10 μM
-
Incubation Time:MG132 or chloroquine pretreatment for 1 h; Zp17 treatment for 24 h
-
Result:MG132 (HY-13259) concentration-dependently attenuated Zp17-induced STING degradation, whereas Chloroquine (HY-17589A) did not significantly reverse the degradation, supporting a proteasome-dependent degradation mechanism.
-
Cell Line:THP-1, RAW264.7, HEK293T,
-
Concentration:5, 10, 20, 40 μM
-
Incubation Time:48 h
-
Result:Exhibited minimal cytotoxicity at all tested concentrations, with high cell survival rates even at 40 μM.
Displayed consistently low cytotoxicity.
-
Cell Line:THP-1
-
Concentration:1.25, 2.5, 5 μM
-
Incubation Time:2 h pretreatment followed by 50 μM MSA-2 (HY-136927) for 4 h
-
Result:Concentration-dependently reduced IFN-β, TNF-α, IL-6 and CXCL10 mRNA expression.
Showed strong inhibition of IFN-β, IL-6 and CXCL10 transcription.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 J (male, 8 weeks old, cisplatin-induced acute kidney injury)[1]
-
Dosage:25 mg/kg
-
Administration:i.p.; once daily; 4 days (starting 1 hour before cisplatin exposure)
-
Result:Reduced cisplatin-induced kidney swelling and pale appearance.
Significantly decreased elevated serum blood urea nitrogen (BUN), creatinine, and uric acid levels.
Reduced elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to a greater degree than SP23.
Suppressed cisplatin-induced upregulation of renal mRNA levels of pro-inflammatory factors IFNβ, TNFα, and IL6.
Ameliorated cisplatin-induced glomerular injury observed via H&E staining.
Caused no overt pathological damage to heart or liver tissue.
化学情報
-
分子量 614.73
-
分子式 C34H42N6O5
-
SMILES
O=C(NC1=CNC2=C1C=CC=C2)NCCCCCCCCCCCCNC3=CC=CC(C(N4C(CC5)C(NC5=O)=O)=O)=C3C4=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)